Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.Closing of the Transact

RBC Capital analyst Alistair Campbell maintains Abcam (NASDAQ:ABCM) with a Sector Perform and lowers the price target from $25 to $24.

Commenting on the report, Jonathan Milner issued the following statement: "I welcome Glass Lewis's scrutiny of the pressing issues surrounding excessive executive pay and bonuses, aspects also recently covered in a Times article, as well as their critical examination of the peer group selection method used for Abcam's valuation. I share these concerns, and these arrangements call for immediate attention. As I have reiterated on numerous occasions, I firmly believe that Danaher's offer of $24 per share significantly undervalues Abcam, offering no premium for control. When considering the potential of Abcam as an independent entity bolstered by an effective Board and Executive Leadership, th

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the CompanyCAMBRIDGE, England, 16 October 2023 – Dr. Jonathan Milner, the founder and one of the largestshareholders in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16%, today issued a presentation covering the reasons for Abcam shareholders to vote against the $24 per share bid from Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher").These include:Data showing that the forward multiple implied by the $24 bid price is below Abcam's long-term trading multipleThe anticipation of a transformational year ahead with increased EBITDA m

RBC Capital analyst Alistair Campbell reiterates Abcam (NASDAQ:ABCM) with a Sector Perform and maintains $25 price target.

Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, today filed and mailed a scheme circular (the 'Scheme Circular‘) in connection with the acquisition of Abcam by Danaher Corporation (NYSE:DHR) (‘Danaher'), announced on August 28, 2023 (the ‘Transaction'). Under the terms of the Transaction Agreement, Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash.The Scheme Circular is available online at Abcam's investor relations website https://corporate.abcam.com/investors/danaher-abcamHighlights from the Scheme Circular include:The Transaction delivers significant, certain, and immediat

KeyBanc Capital Markets analyst Paul Knight reiterated the Overweight rating on Danaher Corporation (NYSE:DHR), lowering the price target to $300 from $325.  Knight notes that after a strong period in 2021 and early 2022, the life science tools sector, including DHR, has been underperforming in FY23. The analyst adds that there have been headwinds due to destocking in consumables used in biological production (such as filters and single-use bags), leading to reduced demand as customers worked down stockpiles in FY23. Additionally, funding for early-stage biotech customers has dried up as exit the pandemic, and weakness in China brought biotech spending to a slow pace during the 2Q23 resul

Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.

Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e

Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat

15% Reported Revenue Growth & 8% Constant Exchange Rate Revenue Growth: Demand for Abcam In-house Products Continues CAMBRIDGE, England and WALTHAM, Mass.  , March 20, 2023 /PRNewswire/ -- Abcam plc (NASDAQ:ABCM) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its results for the year ended 31 December 2022 (the 'period').                                         SUMMARY PERFORMANCE     Year-End 31 December 2022 £m 2021 £m Revenue 361.7 315.4 Gross profit margin, % Adjusted gross profit margin, % 74.8% 75.5% 71.2% 72.2% Operating profit margin, % Adjusted operating profit margin, % Diluted (loss) / earnings per share ('

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc ((AIM LSE: ABC, NASDAQ:ABCM) ("Abcam", "the Company" or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. ("NKY"), for $340 million (the "Acquisition"). Transaction highlights BioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kitsBrings one of Abcam's large third-party suppliers in-houseAccelerates

RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $25.00 from $26.00 previously

Berenberg Bank resumed coverage of Abcam with a rating of Hold

JPMorgan Chase & Co. resumed coverage of Abcam with a rating of Neutral

Royal Bank of Canada resumed coverage of Abcam with a rating of Outperform

SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $25.00 from $26.00 previously

SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $26.00 from $22.00 previously

Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th

Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a

CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight

BRISBANE, Australia, March 18, 2021 /PRNewswire/ -- Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector. Mr Capone spent 17 years with Myriad Genetics, most recently as President and CEO, where he transformed a pioneering start-up into one of the largest precision medicine companies in the world. Mr Capone led Myriad to total annual revenues of more than $800 million and steered the development and launch of more than a dozen reimbursed molecular diagnostics. Prior to Myriad, Mr Capone had a career with Eli Lilly and Company also spanning 17 years, wo

CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Both Bessie and Mark bring extensive and complementary executive and non-executive experience to the Board of Abcam. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink, a China-based venture capital firm and start-up incubator focused on marketing technology, which she founded in 2015. Prior to founding Withinlink, Bessie spent almost three decades at WPP plc, holding Chief Executi